Literature DB >> 26166145

Examining Hepatitis C Virus Treatment Preference Heterogeneity Using Segmentation Analysis: Treat Now or Defer?

Liana Fraenkel1, Joseph Lim, Guadalupe Garcia-Tsao, Valerie Reyna, Alexander Monto.   

Abstract

OBJECTIVE: To improve our understanding of patients' treatment preferences for chronic hepatitis C (HCV).
METHODS: Subjects with HCV were recruited from 2 VA medical centers. Preferences were ascertained using conjoint analysis. We used segmentation analysis to examine whether there were groups of respondents with similar preferences that were systematically different from the preferences of others. We then measured the associations between treatment preference with subjects' characteristics and their gist principles related to living with HCV and the burden of therapy.
RESULTS: A total of 199 subjects participated in this study. The segmentation analysis demonstrated that subjects could be classified into 2 distinct groups. The larger group [group 1, n=118 (59%)] opted for current treatment and the other [group 2, n=81 (41%)] preferred to defer. Patients with cirrhosis were less likely to belong to group 2 (prefer to defer) compared with those without cirrhosis (40.5% vs. 21.3%), whereas subjects self-identifying as African American were more likely to belong to group 2 than white subjects (51.3% vs. 30.5%). Members of group 1 had a more positive overall gist principles related to HCV compared with members of group 2 [mean (SD) score=28.63 (3.06) vs. 26.46 (2.79), P<0.0001]. These gist principles mediated the relationship between race and treatment preference (Sobel test statistic=-2.68, 2-tailed P=0.007).
CONCLUSIONS: Our findings indicate that there are groups of HCV patients with similar preferences that are distinct from other groups' preferences. Patients' gist principles related to the significance of having a chronic viral infection and the burdens of therapy are strongly related to their current treatment decisions. These findings help inform how best to initiate and deliver treatment for patients with HCV.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26166145      PMCID: PMC4811360          DOI: 10.1097/MCG.0000000000000380

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  38 in total

1.  A latent class analysis of age differences in choosing service providers to treat mental and substance use disorders.

Authors:  Amanda Toler Woodward
Journal:  Psychiatr Serv       Date:  2013-11-01       Impact factor: 3.084

Review 2.  Quantifying benefit-risk preferences for medical interventions: an overview of a growing empirical literature.

Authors:  A Brett Hauber; Angelyn O Fairchild; F Reed Johnson
Journal:  Appl Health Econ Health Policy       Date:  2013-08       Impact factor: 2.561

3.  Decision tool to improve the quality of care in rheumatoid arthritis.

Authors:  Liana Fraenkel; Ellen Peters; Peter Charpentier; Blair Olsen; Lanette Errante; Robert T Schoen; Valerie Reyna
Journal:  Arthritis Care Res (Hoboken)       Date:  2012-07       Impact factor: 4.794

4.  Women and their partners' preferences for Down's syndrome screening tests: a discrete choice experiment.

Authors:  Fran E Carroll; Hareth Al-Janabi; Terry Flynn; Alan A Montgomery
Journal:  Prenat Diagn       Date:  2013-03-27       Impact factor: 3.050

5.  Interferon therapy prolonged life expectancy among chronic hepatitis C patients.

Authors:  Haruhiko Yoshida; Yasuyuki Arakawa; Michio Sata; Shuhei Nishiguchi; Michitami Yano; Shigetoshi Fujiyama; Gotarou Yamada; Osamu Yokosuka; Yasushi Shiratori; Masao Omata
Journal:  Gastroenterology       Date:  2002-08       Impact factor: 22.682

6.  Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis.

Authors:  Kris V Kowdley; Stuart C Gordon; K Rajender Reddy; Lorenzo Rossaro; David E Bernstein; Eric Lawitz; Mitchell L Shiffman; Eugene Schiff; Reem Ghalib; Michael Ryan; Vinod Rustgi; Mario Chojkier; Robert Herring; Adrian M Di Bisceglie; Paul J Pockros; G Mani Subramanian; Di An; Evguenia Svarovskaia; Robert H Hyland; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; David Pound; Michael W Fried
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

7.  Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors:  Stefan Zeuzem; Ira M Jacobson; Tolga Baykal; Rui T Marinho; Fred Poordad; Marc Bourlière; Mark S Sulkowski; Heiner Wedemeyer; Edward Tam; Paul Desmond; Donald M Jensen; Adrian M Di Bisceglie; Peter Varunok; Tarek Hassanein; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

8.  Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

Authors:  Jordan J Feld; Kris V Kowdley; Eoin Coakley; Samuel Sigal; David R Nelson; Darrell Crawford; Ola Weiland; Humberto Aguilar; Junyuan Xiong; Tami Pilot-Matias; Barbara DaSilva-Tillmann; Lois Larsen; Thomas Podsadecki; Barry Bernstein
Journal:  N Engl J Med       Date:  2014-04-10       Impact factor: 91.245

9.  Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection.

Authors:  Nezam Afdhal; K Rajender Reddy; David R Nelson; Eric Lawitz; Stuart C Gordon; Eugene Schiff; Ronald Nahass; Reem Ghalib; Norman Gitlin; Robert Herring; Jacob Lalezari; Ziad H Younes; Paul J Pockros; Adrian M Di Bisceglie; Sanjeev Arora; G Mani Subramanian; Yanni Zhu; Hadas Dvory-Sobol; Jenny C Yang; Phillip S Pang; William T Symonds; John G McHutchison; Andrew J Muir; Mark Sulkowski; Paul Kwo
Journal:  N Engl J Med       Date:  2014-04-11       Impact factor: 91.245

10.  Modeling mental health information preferences during the early adult years: a discrete choice conjoint experiment.

Authors:  Charles E Cunningham; John R Walker; John D Eastwood; Henny Westra; Heather Rimas; Yvonne Chen; Madalyn Marcus; Richard P Swinson; Keyna Bracken
Journal:  J Health Commun       Date:  2013-11-22
View more
  5 in total

1.  Using Best-Worst Scaling to Understand Patient Priorities: A Case Example of Papanicolaou Tests for Homeless Women.

Authors:  Eve Wittenberg; Monica Bharel; John F P Bridges; Zachary Ward; Linda Weinreb
Journal:  Ann Fam Med       Date:  2016-07       Impact factor: 5.166

2.  Using Latent Class Analysis to Model Preference Heterogeneity in Health: A Systematic Review.

Authors:  Mo Zhou; Winter Maxwell Thayer; John F P Bridges
Journal:  Pharmacoeconomics       Date:  2018-02       Impact factor: 4.981

3.  Direct-acting antiviral treatment for HIV/HCV patients in safety net settings: patient and provider preferences.

Authors:  Martha Shumway; Anne F Luetkemeyer; Marion G Peters; Mallory O Johnson; Tessa M Napoles; Elise D Riley
Journal:  AIDS Care       Date:  2019-03-04

4.  Adapting a Theoretically-Based intervention for underserved clinical populations at increased risk for hereditary Cancer: Lessons learned from the BRCA-Gist experience.

Authors:  Alejandra Hurtado-de-Mendoza; Valerie F Reyna; Christopher R Wolfe; Sara Gómez-Trillos; Arnethea L Sutton; Ashleigh Brennan; Vanessa B Sheppard
Journal:  Prev Med Rep       Date:  2022-07-05

5.  Viruses, Vaccines, and COVID-19: Explaining and Improving Risky Decision-making.

Authors:  Valerie F Reyna; David A Broniatowski; Sarah M Edelson
Journal:  J Appl Res Mem Cogn       Date:  2021-12-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.